Argentina Starts Clinical Trial with Hyperimmune Equine Serum in Covid-19 Patients

Scientists claim that the treatment is 50 times more capable of neutralizing the virus than the average convalescent plasma.

RIO DE JANEIRO, BRAZIL - To trigger Covid-19, the SARS-CoV-2 virus infects lung cells and other organs through a protein that binds to a receptor. This portion of the virus (the receptor-binding domain - RBD) has been injected by Argentinean scientists into horses, which produced high doses of antibodies with the ability to neutralize the virus' penetration into the cells, as evidenced in in-vitro studies.

After . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?